Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06425926 | Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 117 | Georgiamune IncINDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT02830724 | Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers | recruiting | Phase 1 / Phase 2 | 124 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07696715 | Timing of Immunotherapy in Melanoma(TIME-NL) | recruiting | N/A | 170 | Radboud University Medical CenterOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT00338377 | Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma | active not recruiting | Phase 2 | 1,230 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05308901 | Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma | terminated | Phase 2 | 6 | Providence Health & ServicesOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05859074 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | recruiting | Phase 1 | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07414979 | Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma | not yet recruiting | Phase 1 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07459543 | A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India | not yet recruiting | Phase 4 | 40 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07600476 | A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors | recruiting | Phase 1 | 21 | Kupando GmbHINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07760012 | 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors(SORB-PET) | recruiting | N/A | 50 | Peking University Third HospitalOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07761871 | Exercise and Nutritional Intervention in Patients With Melanoma Receiving Immunotherapy(MEL-FIT-IO) | recruiting | N/A | 40 | Institute of Oncology LjubljanaOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT01989585 | Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma | active not recruiting | Phase 1 / Phase 2 | 75 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2026 | clinicaltrials |
| NCT02581930 | Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04588662 | A Prospective Natural History Study in Uveal Melanoma | active not recruiting | — | 122 | Columbia UniversityOTHER | 5 | Aug 11, 2026 | clinicaltrials |
| NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 250 | MacroGenicsINDUSTRY | 3 | Aug 11, 2026 | clinicaltrials |
| NCT07757386 | MelaMEd Online Training for General Practitioners to Improve Melanoma Detection and Management(MelaMEd) | completed | N/A | 1,531 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT02231775 | Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation | active not recruiting | Phase 2 | 58 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT04594187 | Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma(MelPORT) | recruiting | Phase 2 | 168 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT04855435 | Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours | recruiting | Phase 1 | 106 | MonTa Biosciences ApSINDUSTRY | 2 | Aug 10, 2026 | clinicaltrials |
| NCT06237881 | A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06439979 | Rural Adult and Youth Sun Protection Study(RAYS) | recruiting | N/A | 843 | University of UtahOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07750067 | Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma | recruiting | Phase 2 | 37 | Sun Yat-sen UniversityOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT04099251 | Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma(CheckMate76K) | active not recruiting | Phase 3 | 790 | Bristol-Myers SquibbINDUSTRY | 20 | Aug 7, 2026 | clinicaltrials |
| NCT04899492 | Evaluating Smoking Cessation Protocols in Cancer Patients: NRT, MI, CBT or Hypnotherapy(RESPIRE) | terminated | N/A | 21 | Institut Cancerologie de l'OuestOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07704918 | Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma | recruiting | N/A | 40 | University of Colorado, DenverOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT01979523 | Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma | active not recruiting | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 3 | Aug 6, 2026 | clinicaltrials |
| NCT03991130 | High Dose IL-2 in Combination With Anti-PD-1 | terminated | Phase 2 | 6 | Gregory DanielsOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04221438 | Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement | terminated | Phase 2 | 3 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04386967 | OH2 Injection in Solid Tumors | completed | Phase 1 / Phase 2 | 44 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04527549 | Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma | terminated | Phase 2 | 5 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05581004 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 165 | Genentech, Inc.INDUSTRY | 10 | Aug 6, 2026 | clinicaltrials |
| NCT05600933 | Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment | enrolling by invitation | — | 1,200 | National Cancer Institute (NCI)NIH | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06214156 | A Clinical Study of T3011 in Subjects With Advanced Melanoma | recruiting | Phase 1 / Phase 2 | 42 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06675643 | Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App | recruiting | — | 100 | Mayo ClinicOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT00591500 | A Model for Genetic Susceptibility: Melanoma | active not recruiting | — | 4,082 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT04356729 | A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma | active not recruiting | Phase 2 | 30 | F. Stephen Hodi, MDOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06703398 | A Study of GC101 TIL in Advanced Melanoma(MIZAR-003) | recruiting | Phase 2 | 98 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06910657 | IDOV-Immune for Advanced Solid Tumors | recruiting | Phase 1 | 78 | ViroMissile, Inc.INDUSTRY | 2 | Aug 5, 2026 | clinicaltrials |
| NCT07740941 | NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma | not yet recruiting | Phase 2 | 55 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07747935 | Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma(Uveal Melanoma) | not yet recruiting | Phase 1 / Phase 2 | 30 | ReBio PharmaINDUSTRY | 0 | Aug 5, 2026 | clinicaltrials |
| NCT03698019 | A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma | active not recruiting | Phase 2 | 313 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT04083599 | GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 350 | GenmabINDUSTRY | 12 | Aug 4, 2026 | clinicaltrials |
| NCT05068102 | A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab | active not recruiting | Phase 1 | 14 | Boehringer IngelheimINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT05111574 | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery | active not recruiting | Phase 2 | 101 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT07280715 | Investigating Real-Time Immunotherapy Symptoms Study(IRIS) | recruiting | N/A | 40 | University of PittsburghOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07689812 | A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.(SIGNAL-IO 301) | not yet recruiting | N/A | 920 | Natera, Inc.INDUSTRY | 0 | Aug 4, 2026 | clinicaltrials |
| NCT01024231 | Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma | completed | Phase 1 | 127 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 3, 2026 | clinicaltrials |
| NCT03412058 | Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists(CHECK'UP) | terminated | N/A | 152 | UNICANCEROTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07740642 | A Comparative Usability Study of Two Total Body Skin Imaging Systems | not yet recruiting | N/A | 60 | University Hospital, Basel, SwitzerlandOTHER | 1 | Aug 3, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 14, 2026source: clinicaltrials